BR112023013247A2 - Cargas úteis de esteroide, ligantes de esteroide, adcs contendo os mesmos e seus usos - Google Patents
Cargas úteis de esteroide, ligantes de esteroide, adcs contendo os mesmos e seus usosInfo
- Publication number
- BR112023013247A2 BR112023013247A2 BR112023013247A BR112023013247A BR112023013247A2 BR 112023013247 A2 BR112023013247 A2 BR 112023013247A2 BR 112023013247 A BR112023013247 A BR 112023013247A BR 112023013247 A BR112023013247 A BR 112023013247A BR 112023013247 A2 BR112023013247 A2 BR 112023013247A2
- Authority
- BR
- Brazil
- Prior art keywords
- cells
- steroid
- human
- adcs
- antibody
- Prior art date
Links
- 150000003431 steroids Chemical class 0.000 title abstract 6
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 4
- 210000002865 immune cell Anatomy 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 241000283984 Rodentia Species 0.000 abstract 1
- 230000006044 T cell activation Effects 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 239000000611 antibody drug conjugate Substances 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000003979 eosinophil Anatomy 0.000 abstract 1
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
- 210000000066 myeloid cell Anatomy 0.000 abstract 1
- 210000000822 natural killer cell Anatomy 0.000 abstract 1
- 210000000440 neutrophil Anatomy 0.000 abstract 1
- 231100000683 possible toxicity Toxicity 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 210000003289 regulatory T cell Anatomy 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/0026—Oxygen-containing hetero ring cyclic ketals
- C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
cargas úteis de esteroide, ligantes de esteroide, adcs contendo os mesmos e seus usos. glicocorticosteroides, ligantes do mesmo e conjugados de anticorpo-fármaco (adc) compreendendo anticorpo ou fragmento de anticorpo que se liga a antígeno expresso em células imunes, opcionalmente antígeno expresso em células imunes humanas. em alguns casos, adcs compreendem anticorpo anti-vista humano (supressor de ativação de células t contendo imunoglobulina de região v (1)) ou fragmento de anticorpo de ligação ao antígeno anti-vista que se liga a células que expressam vista em ph fisiológico com uma meia-vida sérica curta ( 24-72 ou 24-48 ou 12-24 horas ou menos em um roedor knockin com vista humano ou ( 1-3,5 dias ou menos em um primata humano ou não humano). em alguns casos, esses adcs têm rápido início de ação e são potentes por duração prolongada, pois são internalizados de forma muito eficaz pelas células imunes em grandes quantidades, onde são clivados, liberando grandes quantidades de carga útil de esteroides ativos. uso de tais adcs e novos esteroides para tratamento de condições autoimunes, alérgicas e inflamatórias. métodos para reduzir os efeitos colaterais adversos e/ou aumentar a eficácia dos agonistas do receptor de glicocorticoides usando tais adcs para distribuir seletivamente esses agentes anti-inflamatórios às células imunes alvo, como monócitos, neutrófilos, células b, células t, tregs, eosinófilos, células nk, macrófagos, células mieloides, et al., e em particular células mieloides, reduzindo assim a toxicidade potencial para células não alvo.
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163134811P | 2021-01-07 | 2021-01-07 | |
US202163138958P | 2021-01-19 | 2021-01-19 | |
US202163178378P | 2021-04-22 | 2021-04-22 | |
US202163186447P | 2021-05-10 | 2021-05-10 | |
US202163188499P | 2021-05-14 | 2021-05-14 | |
US202163246941P | 2021-09-22 | 2021-09-22 | |
US202163251939P | 2021-10-04 | 2021-10-04 | |
US202163271023P | 2021-10-22 | 2021-10-22 | |
US202163271554P | 2021-10-25 | 2021-10-25 | |
US202163284886P | 2021-12-01 | 2021-12-01 | |
US202163290100P | 2021-12-16 | 2021-12-16 | |
PCT/US2022/011687 WO2022150637A1 (en) | 2021-01-07 | 2022-01-07 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023013247A2 true BR112023013247A2 (pt) | 2023-10-03 |
Family
ID=82358345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023013247A BR112023013247A2 (pt) | 2021-01-07 | 2022-01-07 | Cargas úteis de esteroide, ligantes de esteroide, adcs contendo os mesmos e seus usos |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP4271387A1 (pt) |
JP (1) | JP2024502360A (pt) |
KR (1) | KR20230144129A (pt) |
AU (1) | AU2022205664A1 (pt) |
BR (1) | BR112023013247A2 (pt) |
CA (1) | CA3203533A1 (pt) |
IL (1) | IL304059A (pt) |
MX (1) | MX2023008096A (pt) |
TW (1) | TW202241451A (pt) |
WO (1) | WO2022150637A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4308170A1 (en) | 2021-03-18 | 2024-01-24 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
EP4393937A1 (en) * | 2021-08-26 | 2024-07-03 | Duality Biologics (Suzhou) Co., Ltd. | Steroid compound and conjugate thereof |
WO2023040793A1 (zh) * | 2021-09-14 | 2023-03-23 | 映恩生物制药(苏州)有限公司 | 一种抗炎症的化合物及其用途 |
WO2024125639A1 (zh) * | 2022-12-16 | 2024-06-20 | 津药生物科技(天津)有限公司 | 新型糖皮质激素、其制备方法及用途 |
WO2024140838A1 (zh) * | 2022-12-28 | 2024-07-04 | 映恩生物制药(苏州)有限公司 | 抗bdca2抗体-药物偶联物及其用途 |
WO2024153162A1 (en) * | 2023-01-18 | 2024-07-25 | Shanghai Micurx Pharmaceutical Co., Ltd. | Peptide-drug conjugates for targeted therapy of renal diseases |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201139369A (en) * | 2010-02-05 | 2011-11-16 | Chiesi Farma Spa | Pyrrolidine derivatives |
MY194619A (en) * | 2016-06-02 | 2022-12-07 | Abbvie Inc | Glucocorticoid receptor agonist and immunoconjugates thereof |
-
2022
- 2022-01-07 TW TW111100788A patent/TW202241451A/zh unknown
- 2022-01-07 BR BR112023013247A patent/BR112023013247A2/pt unknown
- 2022-01-07 JP JP2023541332A patent/JP2024502360A/ja active Pending
- 2022-01-07 IL IL304059A patent/IL304059A/en unknown
- 2022-01-07 EP EP22737206.7A patent/EP4271387A1/en active Pending
- 2022-01-07 CA CA3203533A patent/CA3203533A1/en active Pending
- 2022-01-07 MX MX2023008096A patent/MX2023008096A/es unknown
- 2022-01-07 KR KR1020237026438A patent/KR20230144129A/ko unknown
- 2022-01-07 AU AU2022205664A patent/AU2022205664A1/en active Pending
- 2022-01-07 WO PCT/US2022/011687 patent/WO2022150637A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP4271387A1 (en) | 2023-11-08 |
MX2023008096A (es) | 2023-09-22 |
AU2022205664A1 (en) | 2023-08-17 |
WO2022150637A1 (en) | 2022-07-14 |
TW202241451A (zh) | 2022-11-01 |
CA3203533A1 (en) | 2022-07-14 |
IL304059A (en) | 2023-08-01 |
KR20230144129A (ko) | 2023-10-13 |
JP2024502360A (ja) | 2024-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023013247A2 (pt) | Cargas úteis de esteroide, ligantes de esteroide, adcs contendo os mesmos e seus usos | |
CN110582280B (zh) | 通过抑制或调节t细胞受体信号传导来治疗t细胞耗竭的方法 | |
Wang et al. | Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events | |
Diehl et al. | Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches | |
Saber et al. | An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates | |
JP5951615B2 (ja) | Tlrアゴニストの治療用途および組み合わせ治療 | |
Brandish et al. | Development of anti-CD74 antibody–drug conjugates to target glucocorticoids to immune cells | |
de Fátima Pereira et al. | The role of the immune system in idiopathic nephrotic syndrome: a review of clinical and experimental studies | |
Groyer et al. | Antiglucocorticosteroid effects suggest why steroid hormone is required for receptors to bind DNA in vivo but not in vitro | |
DE69527050T2 (de) | Bispezifische moleküle mit klinischer verwendbarkeit | |
Norman et al. | PHASE I TRIAL OF HuM291, A HUMANIZED ANTI-CD3 ANTIBODY, IN PATIENTS RECEIVING RENAL ALLOGRAFTS FROM LIVING DONORS1 | |
Kyriakidis et al. | Invasive fungal diseases in children with hematological malignancies treated with therapies that target cell surface antigens: monoclonal antibodies, immune checkpoint inhibitors and CAR T-cell therapies | |
Chan et al. | Angiotensin II causes β-cell dysfunction through an ER stress-induced proinflammatory response | |
Jadoon et al. | Immunotherapy in multiple myeloma | |
Bhatt et al. | CD30 and CD30-targeted therapies in Hodgkin lymphoma and other B cell lymphomas | |
Van Lier et al. | Sex differences in cortisol secretion after administration of an ACTH analogue in sheep during the breeding and non-breeding season | |
Brenneman et al. | Chemokine release is associated with the protective action of PACAP-38 against HIV envelope protein neurotoxicity | |
Radhakrishnan et al. | Preventive azithromycin treatment reduces noninfectious lung injury and acute graft-versus-host disease in a murine model of allogeneic hematopoietic cell transplantation | |
Ho et al. | Current and novel therapies in acute GVHD | |
Spies et al. | Rimexolone inhibits proliferation, cytokine expression and signal transduction of human CD4+ T-cells | |
Pranzatelli et al. | Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonus | |
Olivera et al. | Adenosine stimulates Ca2+ fluxes and increases cytosolic free Ca2+ in cultured rat mesangial cells | |
WO1998008875A1 (de) | Kombinationspräparationen und ihre verwendung in der immundiagnostik und immuntherapie | |
Lee et al. | Wound contraction decreases with intravenously injected substance P in rabbits | |
Noworyta-Glowacka et al. | Influence of chlorpyrifos on the profile of subpopulations of immunoactive cells and their phagocytic activity in an experimental in vivo model |